# BromhexIne And Spironolactone For CoronаVirUs Infection Requiring HospiTalization

> **NCT04424134** · PHASE3 · UNKNOWN · sponsor: **Lomonosov Moscow State University Medical Research and Educational Center** · enrollment: 80 (estimated)

## Conditions studied

- COVID 19

## Interventions

- **DRUG:** Bromhexine and Spironolactone
- **DRUG:** Base therapy

## Key facts

- **NCT ID:** NCT04424134
- **Lead sponsor:** Lomonosov Moscow State University Medical Research and Educational Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-16
- **Primary completion:** 2020-07-18
- **Final completion:** 2020-08-23
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2020-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04424134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04424134, "BromhexIne And Spironolactone For CoronаVirUs Infection Requiring HospiTalization". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04424134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*